Work

Pharmacokinetic (PK)/pharmacodynamic (PD) results from a phase Ib study of pegylated hyaluronidase PH20 (PEGPH20) in combination with gemcitabine (Gem) in patients with pancreatic cancer.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.e15005

Authors: William Proctor Harris, Sunil R. Hingorani, Joseph Thaddeus Beck, Boris A. Berdov, Stephanie Ann Wagner, Eduard M. Pshevlotsky, Sergei Tjulandin, Oleg Gladkov, Randall F. Holcombe, Ping Jiang, Daniel C. Maneval, Joy Zhu, Craig E. Devoe

Institutions: University of Washington, Fred Hutch Cancer Center, Highlands Oncology Group, Medical Radiological Research Center, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center", Russian Cancer Research Center NN Blokhin, Chelyabinsk Regional Clinical Oncology Center, Icahn School of Medicine at Mount Sinai, Halozyme Therapeutics (United States)

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2467429756

Cites:

Cited by: 1

Related to: 10